#USA #Princeton #Reverse Stock Split #CytoSorbents #CTSO

CytoSorbents Corporation Implements Reverse Stock Split

In a significant development for shareholders, CytoSorbents Corporation (NASDAQ: CTSO), renowned for its innovative blood purification technologies aimed at treating critical conditions in intensive care and cardiac surgery, has announced a one-for-twenty reverse stock split. This strategic decision, approved by shareholders at the company’s 2026 Annual Meeting, is set to take effect on September 8, 2026.

Purpose of the Reverse Stock Split

The primary aim of this reverse stock split is to elevate the per-share trading price of CytoSorbents' common stock, thus aiding the company in complying with Nasdaq's minimum bid price requirement of $1.00. By consolidating shares, the company hopes to enhance its attractiveness to investors and ensure its continued listing on the Nasdaq Stock Market. As such, every 20 shares currently held will automatically convert into one new share, leading to a calculated reduction in the total shares outstanding, from approximately 63 million to about 3.1 million after the split is executed.

Implications for Shareholders

Shareholders should note that while the reverse stock split will adjust their number of shares, it is not expected to impact the total dollar value of their investment, except for fractional shares, which will be rounded up to the nearest whole number. Moreover, existing shareholders will retain their proportional ownership in the company post-split.

The move follows trends in the market where companies often opt for reverse stock splits to enhance their stock prices in challenging financial climates. CytoSorbents, which has made pivotal strides in blood purification therapies, particularly amidst the COVID-19 pandemic, is now seeking to stabilize its market position while navigating through market fluctuations.

Regulatory Compliance and Future Outlook

With the successful completion of the reverse stock split, CytoSorbents will continue focusing on its primary mission: providing state-of-the-art therapies for the treatment of life-threatening conditions. The company has also been actively pursuing regulatory approvals for its innovative products, including the DrugSorb-ATR system aimed at mitigating perioperative bleeding in high-risk surgeries.

CytoSorbents is well-known for its flagship product, CytoSorb®, which is approved for use in over 70 countries and has been extensively utilized in clinical settings. This forward-thinking approach not only results in improved shareholder value but also showcases the company’s commitment to developing groundbreaking medical technologies.

Conclusion

Overall, this strategic move underscores CytoSorbents’ determination to comply with Nasdaq regulations while continuing to innovate in the healthcare space. Investors should monitor the developments closely as the company strives to enhance its market presence and continue its journey towards effective treatment solutions for critical care patients.

For further updates, stakeholders are encouraged to stay in touch with the company's official communications and investor relations channels. CytoSorbents remains steadfast in its mission to revolutionize medical treatments through advanced blood purification technologies.